ALPMY Astellas Pharma (ADR)
- 9.720
- -0.180-1.82%
Astellas Pharma (ADR) News
Nikkei average contribution ranking (advance closing) ~ The Nikkei average rebounded, and Omron boosted by about 21 yen with 1 brand
The number of gains and falls of the Nikkei Average constituent stocks at the time of closing 9 days ago was 184 stocks with price increases, 40 stocks with price drops, and 1 stock unchanged. The Nikkei Average rebounded. The front-end transaction was closed at 38392.10 yen (estimated turnover of 840 million shares), which was 189.73 yen higher (+0.50%) compared to the previous day. The US stock market on the 8th was mixed. The Dow average rose by $172.13 (+ 0.44%) to $39056.39, and the Nasdaq depreciated 29.80 points (-0.18%) to 16302.76
J-Front, Kissei Pharmaceutical Industries, etc. (additional) Rating
Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |------|-----------------------------|----------|-------|＜4205＞|Nippon Zeon |SMBC Nikko |1500 yen |1600 yen |＜8056＞|BIPROGY | SMBC Nikko | 3600 yen
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
Nikkei Average Contribution Ranking (big draw) ~ The Nikkei Average continued to decline slightly, and Fast Rite and TDK were pushed down by about 57 yen with 2 stocks
The number of gains and falls of the Nikkei average constituent stocks at the time of the 2-day closing was 2 stocks unchanged, 100 stocks with price increases and 123 stocks with price drops. The US stock market was mixed on May 1. The Dow average closed at 37903.29 dollars, which was 87.37 dollars higher (+ 0.23%), the NASDAQ was 52.34 points lower (-0.33%) at 15605.48, and the S&P 500 closed at 5018.39, which was 17.30 points lower (-0.34%). Private sector employment statistics are mixed to beat expectations
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Poseida Gains on Cell Therapy Pact With Astellas
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences
By Chris Wack Poseida Therapeutics shares were up 18% to $2.86 after the company said it entered into a research collaboration and license agreement with Astellas Pharma's Xyphos Biosciences subsidia
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average fell for the first time in 3 days, and Fast Rite was pushed down by about 49 yen per brand
The number of gains and falls of the Nikkei Average constituent stocks at the time of closing 1 day ago was 44 stocks with price increases, 181 stocks with price drops, and 0 stocks unchanged. The Nikkei Average fell for the first time in 3 days. The forward market transaction was closed at 38189.54 yen (estimated turnover of 880 million shares), which was 216.12 yen lower (-0.56%) compared to the previous day. The US stock market fell on April 30. The Dow average depreciated by $570.17 (-1.49%) at $37815.92, and the Nasdaq depreciated by 325.26 points (-2.04%)
Convertible Stock List (Part 1) [Parabolic Signal Convertible Stock List]
○List of trading stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1377＞ Sakata seed 3605 3505 ＜1379＞ Hokuto 1829 1783 ＜1773＞ YTL 97 77 ＜1814＞ Daisue Ken 1552 1500 ＜1820＞ Nishimatsuken 4543 42 42
Earnings Call Summary | ASTELLAS PHARMA(ALPMF.US) Q4 2023 Earnings Conference
The following is a summary of the Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript:Financial Performance:Astellas reported a year-on-year revenue of JPY1,603.7 billion, marking an increas
Nikkei average contribution ranking (advance closing) ~ The Nikkei Average rebounded, and TOEREC boosted by about 61 yen with 1 brand
The number of gains and falls of the Nikkei Average constituent stocks as of closing 26 days ago was 121 stocks with a price increase and 101 stocks with a price drop of 3 stocks unchanged. The Nikkei Average rebounded. The front-end transaction was closed at 37780.35 yen (estimated volume of 740 million shares), which was 151.87 yen higher (+0.40%) compared to the previous day. The US stock market declined on the 25th. The Dow average depreciated by 375.12 dollars (-0.98%) at 38085.80 dollars, and the NASDAQ depreciated 100.99 points (-0.64%) at 15611.
Nomura FuHD, MinebeaMitsumi, etc. (added) Rating
Downgrading-Bearish Code | Stock Name | Securities Company | Conventional | After Change |------|--------------|--------------|--------------|<2337＞|Ichigo |Morgan S | “Over W” | “Equal W” | Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |----
4/26 [Today's Investment Strategy]
[FISCO Specially Selected Brand] [Material Brand] Yuatec ＜1934＞ 1,321 yen (4/25) Tohoku Electric Power Company. Financial results for the fiscal year ending March 31, '24 have been announced. Operating profit was 10.5 billion yen (up 10.3% from the previous fiscal year). The previous forecast was raised from 9.200 billion yen to 9.60 billion yen on January 30, and it further exceeded that. Operating profit for the fiscal year ending 25/3 is expected to be 12.2 billion yen (up 15.9% from the previous fiscal year). 4 priority businesses (other than Tohoku/Niigata, overseas business, renewable energy-related construction, renewal work
Pay attention to Disco and Astellas drugs, are Shin-Etsu and EXEDY doing well
On the US stock market yesterday 25th, the NY Dow depreciated by 375.12 dollars to 38,085.80, the Nasdaq Composite Index fell 100.99 points to 15,611.76, and the Chicago Nikkei 225 futures were 37665 yen, 55 yen higher than the Osaka Japan-China ratio. The exchange rate is 1 dollar = 155.50-60 yen. In today's Tokyo market, DISCO ＜6146＞, which announced a 59.7% increase forecast for operating income for the 1st quarter, and Astellas Pharma ＜4503＞, which announced an 88.1% increase forecast for operating income for the fiscal year ending 25/3, and the fiscal year ending 25/3
Shin-Etsu, 24/3 operating profit down 29.8% to 701 billion yen
In the financial results for the fiscal year ending 2024/3 announced by Shin-Etsu Ka ＜4063＞, sales were 2,414.937 billion yen, down 14% from the previous fiscal year, and operating profit was 701,038 billion yen, down 29.8% from the same period. In the electronic materials business, the semiconductor market continued to adjust in the fall of the year before last, even in this period, but signs of bottoming out appeared. In the processing/trading/technical service business, demand for semiconductor wafer-related containers continued to be adjusted mainly for in-process use, but automotive input devices were recovering in response to a recovery in the automotive industry
Astellas Pharma Annual Net Plunges, But Revenue Climbs; Expects 2024 Result To Improve
Express News | Astellas 2023/24 Group (Ifrs) Operating Profit 25.52 Bln Yen (-80.8 %), 2024/25 Forecast Profit 48.00 Bln Yen (+88.1 %)
Express News | Astellas 2023/24 Group (Ifrs) Net Profit 17.05 Bln Yen (-82.7 %) , 2024/25 Forecast Profit 30.00 Bln Yen (+76.0 %)
Astellas Pharma FY Oper Pft Y25.52B Vs Pft Y133.03B
Astellas Pharma FY Oper Pft Y25.52B Vs Pft Y133.03B
Astellas Pharma Sees FY Net Y30.00B
Astellas Pharma Sees FY Net Y30.00B
Analysis
Price Target
No Data
